Product
Immunoadsorption + Rituximab + High-dose IVIG
1 clinical trial
1 indication
Indication
High Titers of Anti-HLA AntibodyClinical trial
The Efficacy and Safety of Immunosorbent or Plasma Exchange Combined With Rituximab and High-dose IVIG for Patients With High Titers of Anti-HLA Antibodies Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre, Single-Arm, Phase II Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-31